Baseline demographics of randomised study population in the RITAZAREM trial
| Total (N=170) | Rituximab (N=85) | Azathioprine (N=85) | |
| Age, years: mean (SD) | 57.8 (14.5) | 57.1 (15.1) | 58.6 (13.9) |
| Male, number (%) | 84 (49%) | 43 (51%) | 41 (48%) |
| Race, number (%) | |||
| White | 155 (91%) | 78 (92%) | 77 (91%) |
| Asian | 10 (6%) | 5 (6%) | 5 (6%) |
| Hispanic | 3 (2%) | 2 (2%) | 1 (1%) |
| Black | 0 | 0 | 0 |
| Other | 2 (1%) | 0 | 2 (2%) |
| Disease duration, years: mean (SD) | 7.16 (6.52) | 7.38 (6.94) | 6.93 (6.10) |
| Prior treatment with cyclophosphamide | |||
| Number of patients (%) | 133 (78%) | 67 (79%) | 66 (78%) |
| Cumulative dose, grams (g): mean (SD) | 25.7 (43.3) | 24.4 (50.4) | 26.9 (35.5) |
| Prior rituximab therapy | |||
| Number of patients (%) | 60 (35%) | 33 (39%) | 27 (32%) |
| Cumulative dose, grams (g): mean (SD) | 4.88 (3.24) | 4.47 (2.95) | 5.40 (3.57) |
| Glucocorticoid induction regimen | |||
| 1 mg/kg/day starting dose (1A) | 48 (28%) | 24 (28%) | 24 (28%) |
| 0.5 mg/kg/day starting dose (1B) | 122 (72%) | 61 (72%) | 61 (72%) |
| ANCA type | |||
| Anti-proteinase 3 | 123 (72%) | 61 (72%) | 62 (73%) |
| Anti-myeloperoxidase | 47 (28%) | 24 (28%) | 23 (27%) |
| Relapse type on entry into trial | |||
| Severe | 106 (62%) | 52 (61%) | 54 (64%) |
| Non-severe | 64 (38%) | 33 (39%) | 31 (36%) |